Cardiovascular

Investigators at Loyola University Chicago, Medical Department publish new data on cardiovascular

Published in Pharma Investments, Ventures and Law Weekly, December 13th, 2009

"Celecoxib, rofecoxib, and diclofenac are clinically used cyclooxygenase- 2 (COX-2) inhibitors, which have been under intense scrutiny because long-term rofecoxib (Vioxx; Merck, Whitehouse Station, NJ) treatment was found to increase the risk of adverse cardiovascular events. A differential risk profile for these drugs has emerged, but the underlying mechanisms have not been fully elucidated," scientists in the United States report.

"We investigated the effects of celecoxib, rofecoxib, and diclofenac on ionic currents and calcium signaling in vascular smooth muscle cells (VSMCs) using patch-clamp techniques and fura-2 fluorescence and on arterial constriction using...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2009-12-13)

More Articles from Pharma Investments, Ventures and Law Weekly

A.P. Pharma, Inc.
A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing Requirements
Aafprs
AAFPRS Opposes the Proposed Tax on Medical Procedures
AARP Idaho
Idaho's Members of Congress Turning Blind Eye to State's Health Care Woes
AARP Illinois
AARP Hosts Rep. Bill Foster In Health Care Reform Forum
Alliance HealthCare Services, Inc.
Alliance HealthCare Services Announces Pricing of Private Offering of $190 Million of Senior Notes and Receipt of Commitments for $460 Million Senior Secured Term Loan and $120 Million Revolving Credit Facility
American Academy of Actuaries
Actuaries to Senate: Strengthen Individual Mandate
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry